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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
onabotulinumtoxinA (Botox®) is effective in reducing the number of chronic migraines
(CM) in patients 18-65 years old?
Study Design: Review of three published, double blind randomized controlled trials were
used for this review, which were found on PubMed; were selected based on their relevance to
the clinical question and if they included patient oriented outcomes.
Outcomes Measured: The outcomes measured were headache/migraine free days measured
by >50% responder rate analysis, the Treatment Responder Rate based on Physician Global
Assessment, and total adverse events reported by the participants.
Results: In the study by Mathew et al, onabotulinumtoxinA reported >50% reduction in
HA/migraine days at 3,6,9 months and was consistent if not better when compared to
topiramate (TOPAMAX®). A study by Cady et al. showed the treatment responder rate based
on Physician Global Assessment 9-point scale (+4= clearance of signs and symptoms and -4
=very marked worsening), that by 12 weeks onabotulinumtoxinA treatment when compared
to topiramate had improved chronic migraines (CM) by 79.2% verses 70.8%. Dodick et al,
illustrated that onabotulinumtoxinA against placebo showed a >50% responder rate starting
at week 4 and including 24 weeks. Dodick et al, also looked at total adverse events (AE).
Most adverse events (AE) were mild or moderate in severity and included neck pain, mild
fatigue, nausea and muscular weakness, and resolved without sequelae.
Conclusions: The results of these three randomized controlled trials demonstrate that
onabotulinumtoxinA is safe and effective at treating chronic migraines when compared to
placebo and topiramate.
Key words: Chronic Migraine, OnabotulinumtoxinA
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INTRODUCTION
Chronic migraines (CM) are a debilitating disorder that can be defined as >15
headache days per 30 days for 3 months or more7. CM impairs the quality of life for many
patients, and due to the fact that there are no biological markers for migraines, diagnosis is
made on the clinical history and exclusion of other headache disorders6,7. Acute
pharmacologic and non-pharmacologic treatments have failed to date, so prophylactic
treatments should be investigated as the best option for these patients.
Migraines: including both episodic and chronic, affect 14% of the population and
18% of women6,2. Migraines greatly affect family, work, and social life for many people.
Stressful life events, contraceptive pill use, hypertension, mood changes, and the use or
overuse of certain drugs can increase the frequency of headaches. Dietary changes, regular
sleep, physical activities and relaxation can help to decrease the frequency of them9,2. The
total annual US costs for treating migraines, based on 2010 US census data, was $3.2 billion
for outpatient visits, $700 million for emergency room (ER) visits, and $375 million for
inpatient hospitalizations for migraine; costs totaling near $4.3 billion annually5. Regarding
health care visits each year, there is not an exact estimate, but based off of 2010 US Census
data there were 22,758,044 outpatient visits, and 908,541 ER visits5.
Migraines are generally an inherited condition, one of neuronal hyper-excitability that
sends out impulses to blood vessels, initially causing constriction then vasodilation. The
actual pain that comes with a migraine is caused from the release of prostaglandins,
serotonin, and other inflammatory substances9. The definition of migraine (without aura)
from the second edition of the International Classification of Headache Disorders (ICHD-2)
requires all of the following symptoms: recurrent headaches (at least five lifetime attacks),
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untreated or unsuccessfully treated headache duration of 4-72 hours, at least two of the
following pain characteristics: unilateral, pulsating, moderate or severe intensity, or
aggravated by routine physical activity. The migraine attacks are also associated with at least
one of the following: nausea/vomiting, photophobia, or phonophobia6.
For the acute treatment of CM, conventional therapies such as analgesics, non
steroidal anti-inflammatory drugs (NSAIDS), or migraine specific agents (triptans and ergot
derivatives) have been used6. Medication overuse with these acute therapies can be
hazardous to patients with CM, and it is critical to limit and monitor the use of these when
treating6.
Preventative treatment for CM include: anti-hypertensives, anti-epileptics and antidepressants. Beta blockers, angiotensin converting enzyme inhibitors, angiotensin receptor
blockers, and calcium channel blockers are specific anti-hypertensive medications used to
prevent CM2. Beta blockers, although having top level effectiveness and scientific evidence,
they are contraindicated for many patients; specifically ones with hypotension, congestive
heart failure, asthma, raynauds disease, depression and diabetes2.
Types of anti-epileptic medications are topiramate, valproate, and gabapentin6.
Valproate is often used, and has excellent evidence and clinical effectiveness; however the
use of this medication comes with serious adverse events. Some of which are teratogenicity,
with neural tube defects, polycystic ovarian syndrome, as well as hepatotoxicity when coadministered with other medications2. Many of these drugs have demonstrated efficacy and
safety, however, tolerability issues often arise that attribute to poor adherence to the
prescribed drugs7.
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The goal of chronic migraine prophylaxis is to reduce the frequency of migraines.
With the appropriate prophylaxis treatment, patients should be able to perform daily
activities, and health related quality of life should improve significantly. The MIDAS
(Migraine Disability Assessment Scale) is used to assess the ability to perform daily
activities. Preventative therapy is recommended to be used for periods of months, minimum
of 2 to 3 months of daily administration2. OnabotulinumtoxinA is currently being proposed
to treat CM because it has been shown to be safe, effective and tolerable. Evidence has
shown that onabotulinumtoxinA is effective in reducing myogenic pain associated with
cervical dystonia, chronic limb spasticity, hand dystonia, muscular stress as a migraine
trigger, and pericranial painful muscular trigger points7, 9. Due to its long duration of action,
and lacking the usual side effects caused by prophylaxis, onabotulinumtoxinA is highly
recommended for patients with poor compliance9.
OBJECTIVE
The objective of this selective evidence based medicine (EBM) review is to determine
whether or not onabotulinumtoxinA is effective in reducing the number of chronic migraines
(CM) in patients 18-65 years old.
METHODS
The studies that are included in this review are three randomized, double blind,
placebo controlled clinical trials (RCTs). Two of these RCTs were an open label extension
study. The population studied was males and females aged 18-65 years old, who are
diagnosed with chronic migraines (CM) and are naive to onabotulinumtoxinA treatment.
The interventions used were onabotulinumtoxinA 200 units (100 units fixed site, 100 units
follow-the-pain), plus an oral placebo, compared to 4 week titration of topiramate to
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100mg/day plus placebo saline injections7. Cady et al. also used onabotulinumtoxinA up to
200 units or placebo injected with 100 units into fixed sites; this was compared to topiramate
25mg daily which was increased to 100mg, plus placebo injections1. The last comparison
was made using pivotal trials in the PREEMPT: phase 3 evaluating migraine prophylaxis
therapy clinical program which included a 24 week randomized trial; onabotulinumtoxinA
155 units was administered as 31 fixed-site, fixed dose injections across 7 specific head, and
neck muscle areas, compared to placebo injections in the same locations3. The outcomes
measured were all based on patient oriented evidence that matters (POEMS). The reduction
of headache days per month compared to baseline; the frequency of headache/migraine days
compared to baseline, and the safety and tolerability of the onabotulinumtoxinA treatment.
Key words used in the searches were “onabotulinumtoxinA” and “chronic
migraines.” All articles were published in English, and in peer reviewed journals. The
articles were selected based on their relevance to my clinical question and if they included
patient oriented outcomes. The sources used were researched via Medline, PubMed, and
OVID using key words: OnabotulinumtoxinA, Chronic Migraines.
The inclusion criteria included: Studies that were randomized, controlled, double
blind, and subjects with CM between ages 18-65 years old. Exclusion criteria included:
Subjects <18 years old, and >65 years old, who were pregnant/breast feeding or not using
birth control methods; subjects who had recently used study medications, subjects who had
other co-morbid conditions, articles with diseased oriented evidence (DOE), or articles
published before 1996. Summary statistics were reported using: RBI, ABI, NNT, RRI, ARI
and NNH.
OUTCOMES MEASURED
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The outcomes measured the decrease in frequency of HA/Migraines by 50%
responder rate analysis. Treatment responder rate assessed using the Physician Global
Assessment 9 point scale (+4 = clearance of signs and symptoms and -4 = very marked
worsening). Safety and tolerability was also measured by looking at the nature and frequency
of adverse reactions by treatment related adverse reaction reports.
RESULTS
Two randomized control trials (Mathew, Cady) in this systematic review compared
onabotulinumtoxinA to topiramate, and the third randomized control trial (Dodick) compared
onabotulinumtoxinA to placebo. One of the studies (Cady) studied the two groups
(onabotulinumtoxinA vs. topiramate) for 12 weeks, followed by an open label phase from
week 14-26 for the patients who were considered non-responders. Mathew et al. made
assessments at 1,3,6,9 months. The third study (Dodick) compared onabotulinumtoxinA to
placebo for 24 weeks, followed by a 32 week open label phase including 3 injection cycles.
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Table 1 - Demographics & Characteristics of Included Studies
Study
Dodick2
(2010)

Cady1
(2010)

Type

Age
(yrs)
Double
1384 18blind RCT adults 65
of the
years
PREEMPT
old
clinical
program
(Open
label
phase)

Double
blind RCT
(Open
label
phase)

Mathew6 Double
(2009)
blind RCT

#Pts

Inclusion
Criteria
-age 18-65
years with
a history
of chronic
migraine
meeting
the
diagnostic
criteria

Exclusion
Criteria
Subjects with
continuous
headaches, or if
the subject had
used any
headache
prophylaxis
medication within
4 wks prior to the
start of baseline,
+ urine preg test,
or had previous
exposure to
Botox
59
18-age 18-65 Females who
adults 65
years with were pregnant,
years criteria for breast feeding, or
old
CM
planning to
become pregnant.
Headache
disorders other
than CM, medical
disorders, liver or
renal impairment,
ketogenic diets,
previous
exposure to
Botox/topiramate,
recent
drug/ETOH
abuse
60
18- age 18-65 Females who
adults 65
years with were pregnant,
years criteria for breast feeding, or
old
CM non
planning to
attributable become pregnant.
to another Headache
cause
disorders other
than CM, pts who
previously used
study medications
for any reason

W/D Interventions
0

Randomized to
receive
onabotulinumtoxinA
(155-195U) or
placebo injections
across 31 fixed sites
in two 12 week
injection cycles,
then open label with
3 injection cycles to
32 weeks

15

Randomized to 200
U of
onabotulinumtoxinA
plus placebo tablets,
or topiramate 25mg
daily, escalated to
100mg plus placebo
injections for 12
weeks. Open label
phase for additional
12 weeks.

24

Randomized to
onabotulinumtoxinA
– max 200U dose
plus oral placebo,
compared to
topiramate – 4 wk
titration to
100mg/day, optional
200mg/day plus
placebo saline
injections
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The study by Cady et al. was an open label extension study of 26 weeks from a 12
week experiment. There were 59 participants who began the study and 15 discontinued (8
topiramate and 7 botox subjects). Only 20 subjects (9 from topiramate group and 11 from
onabotulinumtoxinA group) volunteered for the extension1. The comparison of topiramate
(initiated at 25mg and escalated to 100mg) to onabotulinumtoxinA (up to 200 units) looked
at the treatment responder rate based on the Physician Global Assessment 9-point scale (+4 =
clearance of signs and symptoms and -4 = very marked worsening)1. At week 12, the
topiramate group had 17/24 (70.8%) improved compared to 19/24 (79.2%) in the
onabotulinumtoxinA group1. Table 2 shows relative benefit increase for treatment responder
rate at 12 weeks. The relative benefit increase (RBI) was calculated to be 12% and absolute
benefit increase was 8.4%. Numbers needed to treat (NNT) was calculated as 12, meaning
that 12 patients need to be treated with onabotulintoxinA compared to topiramate, in order to
have one person benefit from this type of treatment at 12 weeks.

Table 2: Benefit of onabotulinumtoxinA on treatment responder rate (improvement of
signs/symptoms)
CER

EER

RBI

ABI

NNT

70.8%

79.2%

12%

8.4%

12

The study conducted by Mathew et al. started out with 60 subjects and in the end 24
withdrew from the study (40%). In the topiramate group 24.1% discontinued the study
because of treatment related adverse events, and 7.7% discontinued the study in the
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onabotulinumtoxinA group7. For the 36 who participated in the full length of the study; at six
months of treatment, the onabotulinumtoxinA group (58.3%), and topiramate (31.8%)
reported a >50% reduction in HA/Migraine days, as seen in table 37. The relative risk benefit
(RBI) was calculated to 83.3%, and absolute benefit increase (ABI) was 26.5%. NNT was
calculated to be 4, which means 4 people must be treated with onabotulinumtoxinA for 6
months in order for 1 person to benefit from this treatment when compared to topiramate.

Table 3: Benefit of onabotulinumtoxinA with reduction in HA/Migraine days
CER

31.8%

EER

58.3%

RBI

ABI

NNT

83.3%

26.5%

4

The study by Dodick et al, had 1384 and all participants remained throughout this 24
week study. Of the 688 participants in the onabotulinumtoxinA group, 47.1% at week 24 had
at least 50% decrease from baseline in frequency of headache days when compared to 35.1%
of the 696 participants given placebo3. As shown in table 4, the RBI was 34%, and the ABI
was 12%. The NNT came out to 8, meaning that 8 patients treated with
onabotulinumtoxinA, one person would benefit from this treatment compared to placebo.
Safety and tolerability was looked at, and the nature and frequency of the adverse
events (AE’s) were similar for both groups3. Most AE’s were mild to moderate; total adverse
events occurred in 62.4% of patients in the onabotulinumtoxinA group, and 51.7% of the
patients in placebo group, as shown in table 53. The RRI was 20.7%, ARI was 10.7%. The
numbers needed to harm (NNH) was calculated to be 9; this means that if 9 patients were
treated with onabotulinumtoxinA for 24 weeks, one more person would be harmed by the
treatment than control. Table 6 shows overall AEs reported in the 24 week, double bind
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phase. Serious adverse events only occurred in 4.8% of the onabotulinumtoxinA group and
2.3% in the placebo group. No deaths were reported from this study3.
Table 4: Benefit of onabotulinumtoxinA at frequency of headache days from baseline to all
time points
CER

EER

RBI

ABI

NNT

35.1%

47.1%

34%

12%

8

Table 5: All AE’s from the onabotulinumtoxinA injections when compared to placebo
CER

EER

RRI

ARI

NNH

51.7%

62.4%

20.7%

10.7%

9

Table 6: Summary of Overall AEs reported in 24 weeks3
OnabotulinumtoxinA

Placebo (692)

(687)
All adverse events

492 (62.4%)

358 (51.7%)

Treatment related AEs

202 (29.4%)

88 (12.7%)

Serious adverse events

33 (4.8%)

16 (2.3%)

Treatments related,
serious AEs
Discontinuations related
to AEs
Death

1 (0.1%)

0 (0.0%)

26 (3.8%)

8 (1.2%)

0 (0.0%)

0 (0.0%)
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DISCUSSION
This systematic review investigated three RCTs for the effectiveness of
onabotulinumtoxinA in reducing the number of chronic migraines (CM) in patients 18-65
years old. All of these studies demonstrated the effectiveness of onabotulinumtoxinA in
reducing the frequency of CMs, and demonstrating a treatment response rate where signs and
symptoms of CMs were reduced. The study by Dodick et al, demonstrated that this drug is
also safe and tolerable when compared to placebo.
Until recently, patients with CM have been excluded from prophylaxis trials because
the thought was that they are treatment resistant3. However, due to the amount of people
who suffer from this terrible illness, it calls for some attention. OnabotulinumtoxinA is FDA
approved for chronic migraines (≥15 days/month with ≥4 hours/day headache duration) in
adults. Administration of the drug is by a 30 gauge needle to a total of 31 sites8. As of right
now, if used chronically, the long term effects are unknown.
There are various limitations among the studies presented in this review. In the Cady
et al. study, the use of an active comparator rather than placebo, may have made the study
stronger. The investigators in this study were more sophisticated in the evaluation of
migraine response than the broader population of physicians treating migraines; therefore, it
does not reflect accurate clinical assessment. The sample size of 44 may not have been
sufficient enough to represent the CM population. A small sample size of only 40 also
occurred in the study done by Mathew et al. In addition, Dodick et al. did not include an
active comparator, nor was there a notable placebo response in this study.
CONCLUSION
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OnabotulinumtoxinA is a safe and effective treatment for chronic migraine
prophylaxis and treatment. The treatment response rate and decrease in number of migraines
was statistically significant in all three studies. Future studies need to incorporate cost of this
treatment along with its effectiveness, compared to other treatments. If this treatment
becomes popular and is widely used in the future, it would be important to examine the long
term side effects of this drug. Continued research on onabotulinumtoxinA for prophylactic
use for chronic migraines will be very beneficial to patients who do not have control with
other medications.
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